Clinical Trial Update: Phase I/II Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD) [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial update evaluating PRL3-zumab for neovascular age-related macular degeneration; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• PRL3-ZUMAB

Snippet

Sponsor: Intra-IMMUSG Pte Ltd | Conditions: Neovascular Age Related Macular Degeneration | Phase 1, Phase 2 | Status: RECRUITING